ES2983492T3 - Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos - Google Patents
Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos Download PDFInfo
- Publication number
- ES2983492T3 ES2983492T3 ES17757849T ES17757849T ES2983492T3 ES 2983492 T3 ES2983492 T3 ES 2983492T3 ES 17757849 T ES17757849 T ES 17757849T ES 17757849 T ES17757849 T ES 17757849T ES 2983492 T3 ES2983492 T3 ES 2983492T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- group
- antigen
- binding portion
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614162.4A GB201614162D0 (en) | 2016-08-18 | 2016-08-18 | Antibodies, uses thereof and conjugates thereof |
| PCT/GB2017/052448 WO2018033749A1 (en) | 2016-08-18 | 2017-08-18 | Anti-psma antibodies, uses thereof and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2983492T3 true ES2983492T3 (es) | 2024-10-23 |
Family
ID=57045541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17757849T Active ES2983492T3 (es) | 2016-08-18 | 2017-08-18 | Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11059903B2 (https=) |
| EP (2) | EP3500595B1 (https=) |
| JP (2) | JP7039554B2 (https=) |
| CN (1) | CN110049999B (https=) |
| ES (1) | ES2983492T3 (https=) |
| GB (1) | GB201614162D0 (https=) |
| WO (1) | WO2018033749A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| US12059473B2 (en) * | 2018-03-29 | 2024-08-13 | Ambrx, Inc. | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates |
| BR112021026663A2 (pt) * | 2019-07-02 | 2022-04-12 | Telix Int Pty Ltd | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal |
| WO2021050656A1 (en) | 2019-09-11 | 2021-03-18 | The Trustees Of The Univeristy Of Pennsylvania | Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars) |
| WO2021098834A1 (zh) * | 2019-11-22 | 2021-05-27 | 上海一宸医药科技有限公司 | Psma抗体及其应用 |
| CN110922486B (zh) * | 2020-02-18 | 2020-05-22 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2024182569A2 (en) * | 2023-02-28 | 2024-09-06 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CA2232818C (en) | 1996-07-24 | 2006-06-06 | Philips Electronics N.V. | Improvements in and relating to optically readable discs and disc recording apparatus |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| BRPI0607796A2 (pt) * | 2005-02-18 | 2009-06-13 | Medarex Inc | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica |
| NZ556661A (en) | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
| WO2009017823A2 (en) * | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| KR20100090684A (ko) | 2007-10-09 | 2010-08-16 | 폴리테릭스 리미티드 | 신규한 접합 단백질 및 펩티드 |
| CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| MX2014015682A (es) * | 2012-06-19 | 2015-07-23 | Polytherics Ltd | Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos. |
| MX2015005122A (es) * | 2012-10-24 | 2015-10-29 | Polytherics Ltd | Conjugados de farmaco-proteina novedosos. |
| NO2789793T3 (https=) | 2012-10-24 | 2018-01-27 | ||
| WO2015142314A1 (en) * | 2013-03-15 | 2015-09-24 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| US20150110814A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| ES2895623T3 (es) * | 2014-05-22 | 2022-02-22 | Byondis Bv | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
-
2016
- 2016-08-18 GB GBGB1614162.4A patent/GB201614162D0/en not_active Ceased
-
2017
- 2017-08-18 CN CN201780044227.8A patent/CN110049999B/zh active Active
- 2017-08-18 EP EP17757849.9A patent/EP3500595B1/en active Active
- 2017-08-18 WO PCT/GB2017/052448 patent/WO2018033749A1/en not_active Ceased
- 2017-08-18 JP JP2019502698A patent/JP7039554B2/ja active Active
- 2017-08-18 EP EP24173428.4A patent/EP4403226A3/en active Pending
- 2017-08-18 US US16/303,600 patent/US11059903B2/en active Active
- 2017-08-18 ES ES17757849T patent/ES2983492T3/es active Active
-
2022
- 2022-03-08 JP JP2022035222A patent/JP7486538B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11059903B2 (en) | 2021-07-13 |
| GB201614162D0 (en) | 2016-10-05 |
| JP7039554B2 (ja) | 2022-03-22 |
| EP4403226A2 (en) | 2024-07-24 |
| JP7486538B2 (ja) | 2024-05-17 |
| EP4403226A3 (en) | 2024-10-16 |
| JP2022084715A (ja) | 2022-06-07 |
| CN110049999B (zh) | 2023-12-19 |
| JP2019535232A (ja) | 2019-12-12 |
| EP3500595B1 (en) | 2024-05-01 |
| CN110049999A (zh) | 2019-07-23 |
| EP3500595A1 (en) | 2019-06-26 |
| US20190300623A1 (en) | 2019-10-03 |
| WO2018033749A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2983492T3 (es) | Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos | |
| JP7564176B2 (ja) | 抗体、その使用及びそのコンジュゲート | |
| JP7016975B2 (ja) | ナノ粒子イムノコンジュゲート | |
| ES2769538T3 (es) | Kit de predireccionamiento, método y agentes que se usan en éste | |
| ES2874493T3 (es) | Sitios específicos para modificar anticuerpos para generar inmunoconjugados | |
| CN106995493B (zh) | 氯毒素多肽和结合物及其应用 | |
| US20190375837A1 (en) | Immunocytokine combination therapy | |
| ES2747727T3 (es) | Composiciones y métodos para el diagnóstico y tratamiento del cáncer | |
| ES2913401T3 (es) | Nuevo fragmento Fab de anticuerpo anti-MUC1 humana | |
| US20180078654A1 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| KR20220015504A (ko) | 단백질-폴리머-약물 접합체 | |
| ES2625829T3 (es) | Conjugados y sus usos en la obtención de imágenes moleculares | |
| WO2025209500A1 (zh) | Nectin-4单域抗体及其用途 | |
| TW201708407A (zh) | 螢光綴合物 | |
| EP4612189A1 (en) | Radionuclide and near-infrared dye conjugated antibody for detection of gd2-positive cancer | |
| CN121866076A (zh) | 新型治疗靶标 | |
| Guley | Serum Albumin as a Carrier of Immunostimulatory Oligodeoxynucleotides for Cancer Therapy | |
| BR112017020689B1 (pt) | Imunoconjugado comprendendo uma nanopartícula revestida com um políomero orgânico e um fragmento de anticorpo conjugado à mesma |